NRXP Share Price Performance
US$3.35
1.85 (123.33%)
Price US$3.35
Share PriceUS$3.35
NRx Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
NRXP Community Narratives
There are no narratives available yet.
Recent NRXP News & Updates
NRx Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.42
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -27.7%
NRx Pharmaceuticals, Inc. Competitors
Snowflake Analysis
About NRXP
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.9% in the Information Technology sector. As for the past 12 months, the market is up 19%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›